Boston, MA
Boston’s most valuable biotech? It’s not who you might expect. – The Boston Globe
“Biogen has been type of the highest canine within the Boston biotech neighborhood for a few years,” mentioned John Maraganore, former chief govt of Cambridge-based Alnylam Prescribed drugs. “However now we see Vertex rising to the highest, applicable to their title.”
How the corporate received there by dominating the drug marketplace for a single long-untreatable illness is without doubt one of the metropolis’s greatest biotech success tales, and it’s not over but.
Extremely, Vertex has constructed its empire by promoting simply 4 life-changing medication for cystic fibrosis, a uncommon genetic situation that predominantly impacts the lungs and digestive system. Due to these capsules, sufferers are respiratory simpler, feeling extra energetic, and beginning to reside longer, too.
The corporate has turn out to be more and more engaging to buyers partly as a consequence of its higher-than-expected gross sales of these medication, which have little competitors on the horizon, and its plans to broaden into different illnesses.
“Vertex has actually benefited from a extra skittish, risk-averse biotech market proper now, and it’s been a kind of distinctive sorts of ‘Goldilocks’ shares that has progress, but in addition has safety,” mentioned Paul Matteis, a biotechnology analyst on the funding agency Stifel.
Over the previous yr, Vertex has unveiled promising knowledge on a non-addictive painkiller that might present an alternative choice to opioids; a gene-editing remedy developed with Cambridge-based CRISPR Therapeutics that might heal damaged blood cells in sickle cell illness; and a stem cell-derived remedy that might turn out to be a long-awaited remedy for sort 1 diabetes.
“The corporate is at a brand new inflection level at this time,” Vertex chief govt Dr. Reshma Kewalramani mentioned in an interview. “What we need to do is replicate what we’ve completed in cystic fibrosis and remodel, if not remedy, a number of further illnesses.”
Though many of those packages had been underway earlier than Kewalramani grew to become CEO in April 2020, she saved pushing them ahead throughout the pandemic.
The agency has doubled down on cutting-edge medicines with the opening of a brand new lab and manufacturing facility within the Seaport devoted to cell and gene therapies. About 3,100 of the corporate’s 4,300 workers are primarily based in Boston, and extra jobs are on the way in which with a deliberate enlargement within the Seaport.
Fueling this progress are the agency’s extremely efficient, and extremely worthwhile, capsules for cystic fibrosis, which made $7.57 billion in gross sales final yr. The overwhelming majority of that got here from a single drug, Trikafta, which was permitted in 2019 and prices $311,500 per affected person a yr. Whole revenues might rise to $8.8 billion this yr, and better nonetheless in years to return as Trikafta turns into obtainable in additional international locations and for youthful ages.
Though Vertex has been a giant title in Boston’s biotech neighborhood for many years, the agency’s present degree of success was by no means assured.
“I at all times considered them as Genzyme’s and Biogen’s little brother,” mentioned Kenneth Kaitin, a professor of drugs and drug trade professional at Tufts College College of Drugs. Whereas Genzyme pioneered therapies for uncommon illnesses and Biogen for a number of sclerosis, “there was poor Vertex trying to play with the large boys, however they’d no marketed merchandise,” he added.
Within the twenty years after it was based by Joshua Boger in 1989, Vertex burned via billions of {dollars} attempting to make medicines for most cancers, viral infections, and different illnesses. The corporate’s massive break got here in 2011 with the approval of Incivek, a hepatitis C therapy. Gross sales shortly topped $1 billion in 2012 earlier than evaporating over the following two years when a competitor launched a more practical drug.
“We received out-innovated,” mentioned Stuart A. Arbuckle, the chief business and operations officer. “That was a painful lesson to be taught.”
Vertex used its income from Incivek to keep away from the same failure in cystic fibrosis. The corporate’s first drug for the illness, Kalydeco, was permitted in 2012 to assist stabilize the precise proteins, referred to as CFTR, which might be essential for clearing mucus from the airways however are damaged or lacking in folks with cystic fibrosis.
That first tablet solely labored for about 4 p.c of sufferers. Over the following eight years, beneath CEO Jeffrey Leiden, the corporate rolled out three extra medication, culminating with Trikafta, which stabilizes CFTR proteins in additional than 90 p.c of sufferers with cystic fibrosis.
Dr. John P. Clancy, vice chairman of medical analysis for the Cystic Fibrosis Basis, mentioned Vertex’s medicines cut back the period of time sufferers spend on every day care, similar to clearing mucus that accumulates to harmful ranges of their airways. “It’s essentially altering how their life is lived.”
Vertex has one more medication for the illness in superior medical research that might wrap up by early 2023. Kewalramani thinks the brand new tablet might enhance the well being of sufferers much more dramatically than Trikafta, could possibly be taken as soon as a day as a substitute of twice a day, and will probably enhance Vertex’s income even additional.
The corporate’s dedication to bettering its cystic fibrosis medication has made it arduous for potential opponents, together with AbbVie, whose experimental capsules have underperformed in comparison with Trikafta. If Vertex’s new drug proves higher nonetheless, the corporate will strengthen its efficient monopoly on therapies for the illness.
The agency’s success hasn’t come with out criticism. Vertex has confronted some resistance from European well being care methods over its costly drug costs. And the Institute for Scientific and Financial Evaluate, or ICER, a drug-pricing watchdog, concluded that Trikafta would should be discounted no less than 73 p.c — or price not more than $85,500 a yr — to be thought-about cost-effective.
“No one can remorse the innovation that has led to the present lineup of cystic fibrosis medication,” mentioned ICER president Dr. Steve Pearson. “However even when you will have a drug that’s actually significantly better than what sufferers had earlier than, it’s attainable for the drug to be overpriced.”
A latest survey of Fortune 500 firms underscores simply how worthwhile Vertex’s medication are. The agency reaped about $798,000 per worker in 2020, making it essentially the most worthwhile firm by that measure within the drug trade and the sixth most worthwhile general — beating out tech and finance giants Alphabet, Apple, Meta, Microsoft, and Visa.
An unusually small salesforce, which numbers simply 16 folks within the US, helps preserve Vertex’s prices down — partly as a result of they’re the one recreation on the town for cystic fibrosis. An estimated 83,000 folks have the illness within the firm’s main markets of Australia, Canada, Europe, and the US.
Kewalramani mentioned Vertex is engaged on a one-time gene remedy for the illness. However technical challenges which have stumped scientists for many years might not be resolved any time quickly. In the meantime, Vertex is partnering with Moderna on an inhalable mRNA remedy that will assist sufferers who’re missing CFTR altogether make the essential protein of their lungs. A medical trial of that strategy might start subsequent yr.
Vertex can be within the early phases of growing a number of totally different stem-cell-derived therapies for sort 1 diabetes that it acquired by buying two startups, Semma Therapeutics and ViaCyte.
These stem cell therapies, in addition to the corporate’s CRISPR gene-editing work on genetic blood illnesses and muscular dystrophies, mark a radically new path for Vertex, which has lengthy centered on growing pill-based medication designed by chemists. However chief scientific officer Dr. David Altshuler mentioned these new packages match squarely in Vertex’s wheelhouse of engaged on illnesses the place the foundation trigger is nicely understood and there’s a transparent technique for learn how to deal with it.
Biotech analysts say it’s arduous to level to any single experimental remedy as the primary driver of the corporate’s inventory efficiency.
“The overwhelming majority of large-cap biotech firms find yourself getting constructed on one or two actually massive drug franchises after which have problem in reinventing themselves as soon as competitors emerges,” Matteis, the Stifel analyst, mentioned.
However Vertex is attempting arduous to buck that development. Final yr, the corporate spent greater than 40 p.c of its income on analysis and improvement of recent medication — excess of most pharma firms.
And for the reason that firm is sitting on about $9.3 billion in money, buyers are questioning if Vertex will purchase one other agency. Kewalramani acknowledged that “there are good values available,” however that any acquisitions would wish to align with the agency’s analysis technique.
“The one factor I can let you know is Vertex goes to develop,” Kewalramani mentioned. “And headquarters for us is true right here in Boston.”
Ryan Cross could be reached at ryan.cross@globe.com. Comply with him on Twitter @RLCscienceboss.
Boston, MA
Watch New Orleans Pelicans vs. Boston Celtics free live stream
There is NBA action on Sunday, Jan. 12 that sees the Boston Celtics welcoming the New Orleans Pelicans to TD Garden in Boston.
The game is scheduled to start at 6 p.m. EST and will be broadcast on NBC Sports Boston. Fans looking to watch this NBA game can do so for free by using DirecTV Stream, which offers a free trial. You can also watch on FuboTV, which also offers a free trial and $30 off your first month, or SlingTV, which doesn’t offer a free trial but has promotional offers available.
The Celtics have lost two of their last three and are 11-8 since the start of December, and now sit at 27-11, still the second-best mark in the East. The Pelicans are 8-31, but have won three of their last five.
- WATCH THE GAME FOR FREE HERE
Who: New Orleans Pelicans vs. Boston Celtics
When: Sunday, Jan. 12 at 6 p.m. EST
Where: TD Garden in Boston
Stream: FuboTV; Sling; DirecTV Stream (free trial)
Betting: Check out our MA sports betting guide, where you can learn basic terminology, definitions and how to read odds for those interested in learning how to bet in Massachusetts.
What is FuboTV?
FuboTV is an internet television service that offers more than 200 channels across sports and entertainment including Paramount+ with SHOWTIME. From the UEFA Champions League to the WNBA to international tournaments ranging across sports, there’s plenty of options available on FuboTV, which offers a free trial and $30 off the first month for new customers.
What is DirecTV Stream?
DirecTV Stream offers practically everything DirecTV provides, except for a remote and a streaming device to connect to your television. Sign up now and get three free months of premium channels including MAX, Paramount+ with SHOWTIME and Starz.
What is SlingTV?
SlingTV offers a variety of live programing ranging from news and sports and starting as low as $20 a month for your first month. Subscribers also get a month of DVR Plus free if they sign up now. Choose from a variety of sports packages without long-term contracts and with easy cancelation.
RELATED CONTENT:
An NBA 1st: Jokic, Westbrook record triple-doubles in same game for 2nd time this season
By MICHAEL KELLY Associated Press
DENVER (AP) — Denver’s Nikola Jokic and Russell Westbrook made NBA history on Friday night, becoming the first pair of teammates to record a triple-double in the same game multiple times in a single season.
Jokic finished with 35 points, 15 assists and 12 rebounds for his NBA-leading 15th triple-double of the season in the Nuggets’ 124-105 win over the Brooklyn Nets. Westbrook had 25 points, 11 rebounds and 10 assists.
“I think it’s that’s the style both of us play,” Jokic said. “I’m just glad we’re winning the games because that’s more important than the stats. It’s special, the relationship, how the guys are willing to run the lanes and get to the corner. They know the ball’s going to find them.”
They’re also the first to record a 25-point triple-double in the same regular-season game.
“Wow. That’s pretty crazy. We’re watching history, folks,” Denver coach Michael Malone said.
The pair also accomplished the feat at Utah on Dec. 30. Jokic had 36 points, 22 rebounds and 11 assists that night while Westbrook had 16 points, 10 rebounds and 10 assists.
Westbrook made all seven of his shot attempts, both free throw attempts and didn’t have a turnover in that game.
Westbrook credited Malone with giving him the freedom to play his game.
“Being able to do that allows me to be able to make guys around me better,” Westbrook said Friday. “Try to bring this team some leadership, some energy, some toughness. We’re just getting started on figuring it out.”
Jokic had missed the previous two games with an illness before returning against the Nets. He went to the bench late in the third quarter one rebound shy of his 145th career triple-double and the Nuggets leading by 18.
Brooklyn rallied to get within five and Jokic returned and had nine points, four assists and three rebounds in the fourth.
Jokic got his 10th rebound after Westbrook blocked Keon Johnson’s shot with 6:51 left.
Westbrook had four assists in the fourth to record his 202nd career triple-double, which is the most in an NBA career. It was his third triple-double this season, his first in Denver.
Westbrook signed with the Nuggets last summer after spending the last three seasons in Los Angeles with both the Lakers and the Clippers.
The Associated Press contributed to this article
Boston, MA
Maguire & Caldarone: Bilingual education a must for BPS students
The Boston Public Schools (BPS) enroll students from 139 different countries who speak 66 different languages at home. Roughly one-third of BPS students are classified as Multilingual Learners or English Language Learners (ELs), which means they are not fluent in English and need their instruction augmented in some way.
It’s the “in some way” which is the topic of intense debate both locally and nationally. The Boston Teachers Union (BTU) wants to change the way the BPS teaches EL students. The BTU wants the BPS to end its current practice of having a general education teacher also deliver English language instruction. President-elect Donald Trump recently told Time magazine that he wants to keep only some of the Department of Education operational “just to make sure they’re teaching English in the schools.”
In an effort to help ELs, the BPS recently announced the creation of new dual language programming for the ‘25-’26 school year. At first only 200 students will be served but expansions are planned. These programs range from “newcomers” who do not speak any or only very limited English, to advanced programs in high school where students are eligible to receive the Massachusetts State Seal of Biliteracy upon graduation.
All of these approaches only nibble around the edge of the issue, and even if these programs are faithfully implemented the core issue remains unchanged: American students are at a disadvantage globally if they remain monolingual.
Finland, often hailed as the world exemplar of public education, requires its students to learn four languages by the time they graduate secondary school. Finland has two official languages, Finnish and Swedish. Whatever language a student speaks at home, that student learns the other official language in school. The goal is to have all Finns able to speak to one another in order both to build a national community and to make commerce easier. Then Finns learn two more languages (one of which is usually English).
Over 43 million people in the United States speak Spanish at home (13% of the population). In Boston,16% of the population speaks Spanish. So let’s follow the Finnish model and have all our students – and citizens – understand one another.
Boston already has a few dual-language programs in not only Spanish but also in Haitian Creole, Vietnamese, and American Sign Language. What if Boston simply expanded these programs so that all students in the BPS became proficient in at least two languages?
If this were to happen, then Boston graduates would be in high demand. A 2023 report by The Century Foundation states that bilingual students have better problem-solving skills and improved working memory due to their more active neural networks as a result of their learning two (or more) languages.
There are other benefits of bilingualism such as better social-emotional development and even a potential delay in the onset of Alzheimer’s disease (again due to expanded neural pathways).
Practically speaking, bilingual employees can earn up to 20% more than their monolingual counterparts. Workforce Essentials reported in 2023 that US businesses lose roughly $2 billion annually due to language barriers and cultural misunderstandings. Undeniably our world is becoming more interconnected. BPS graduates who are multilingual would have a great advantage in both college and career.
Boston is already moving in the direction of increased multilingual instruction. In the Dec. 18, 2024 School Committee meeting, BPS interim CFO David Bloom gave a report which stated that over the past year the general education population in the BPS decreased by 22% whereas the number of ELs increased by 11%. Simply put, Boston has to increase its multilingual instruction anyway. Why not go all in?
There are two frequent arguments against bilingual education. One is xenophobia and the other is parsimony. For a “nation of immigrants” it is illogical for us to fear our neighbors’ words and cultures. As for the cost, let us beware of the “bait and switch” of vouchers or school choice.
It is also important to also note that many private/independent schools offer language instruction from Grade 1 through Grade 12. They know that doing so will make their graduates more competitive in college and beyond.
There is no denying that Boston needs to do better by its students. If we continue the current model we will likely continue with the current results. An expansive bilingual program would both improve our students’ lives and attract more families to the district.
Finally we could also help our students and families by having our teachers learn Spanish and/or other languages in their professional development sessions. We can all learn from each other.
Para los estudiantes de hoy, la educación bilingüe es esencial para la universidad, la carrera y nuestra sociedad global. Creemos que todos los estudiantes deberían tener la misma oportunidad de aprender otros idiomas.
(Michael Maguire teaches Latin and Ancient Greek at Boston Latin Academy and serves on the Executive Board of the Boston Teachers Union. Julie Caldarone is the retired Director of World Languages for Boston Public Schools. She currently co-teaches a course entitled, “Spanish for BPS Educators.” The ideas expressed here are their own.)
Boston, MA
Red Sox Icon David Ortiz Urges Boston To ‘Make It Rain’ For Free-Agent Slugger
The Boston Red Sox hive mind doesn’t always come to a perfect agreement on what they want the team to do. That is, of course, unless David Ortiz is asking for it.
A three-time World Series champion, Hall of Famer, and one of the most clutch players of all time, Ortiz is unquestionably on the Red Sox’s all-time Mount Rushmore. Even though he retired in 2016, he’s still closely woven into the fabric of the organization.
Ortiz sees what we all do: this Red Sox team is close to being ready to contend for the playoffs, but there’s one key ingredient missing. He made his feelings known about what he hopes the front office does between now and Opening Day to address that issue.
On Saturday, Ortiz relayed a simple message to the Red Sox: spend whatever it takes to get one more big bat.
“There’s still some guys out there that we can still go for, and I think we have a really good front office,” Ortiz said in an appearance on NESN. “To put a good lineup together nowadays is not that difficult. What you got to do is just make it rain, and you can go pick a few guys. Now pitching, on the other hand, is the toughest thing to put together.
“We got pitching. Pitching can always stop good offenses. The playoff is a playoff pitching (staff) we got right now. We line up a couple of thunders in the lineup to help (Rafael Devers) and the rest of them boys — one good bat would do.”
Ortiz and NESN host Tom Caron both strongly hinted at the end of the interview who that big bat could be: former Houston Astros All-Star Alex Bregman. Manager Alex Cora also signaled earlier in the day that Bregman would be a great fit in Boston.
Bregman isn’t quite Ortiz, but he does have one thing on him: the career record for OPS at Fenway Park. He has a wild 1.245 mark in 98 plate appearances in Boston throughout his career.
When David Ortiz asks for something, the Red Sox would usually be wise to follow through. And it seems he wants Bregman. Will that move the needle in the suites at Fenway?
More MLB: Red Sox Predicted To Land Ex-Padres $28 Million Gold Glover In Free Agency Surprise
-
Politics1 week ago
New Orleans attacker had 'remote detonator' for explosives in French Quarter, Biden says
-
Politics1 week ago
Carter's judicial picks reshaped the federal bench across the country
-
Politics1 week ago
Who Are the Recipients of the Presidential Medal of Freedom?
-
Health7 days ago
Ozempic ‘microdosing’ is the new weight-loss trend: Should you try it?
-
World1 week ago
South Korea extends Boeing 737-800 inspections as Jeju Air wreckage lifted
-
Technology3 days ago
Meta is highlighting a splintering global approach to online speech
-
World1 week ago
Weather warnings as freezing temperatures hit United Kingdom
-
News1 week ago
Seeking to heal the country, Jimmy Carter pardoned men who evaded the Vietnam War draft